Supplemental material
Open access
5,668
Views
4
CrossRef citations to date
0
Altmetric
Articles
An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan
Hidehisa Saekia Department of Dermatology, Nippon Medical School, Tokyo, JapanView further author information
, Kanako Ishiib Market Access, AbbVie GK, Tokyo, JapanView further author information
, Avani Joshic Dermatology Health Economics and Outcomes Research, AbbVie Inc, Mettawa, IL, USAView further author information
, Arielle G. Bensimond Health Economics and Outcomes Research, Analysis Group, Inc, Boston, MA, USACorrespondence[email protected]
View further author information
, View further author information
Hongbo Yangd Health Economics and Outcomes Research, Analysis Group, Inc, Boston, MA, USAView further author information
& Isao Kawaguchib Market Access, AbbVie GK, Tokyo, JapanView further author information
Pages 229-239
|
Received 27 Feb 2020, Accepted 15 Mar 2020, Published online: 17 Apr 2020
Related Research Data
An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].
Source:
Elsevier BV
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Source:
Massachusetts Medical Society
Research for Willingness to Pay for One QALY Gain
Source:
The Health Care Science Institute
The impact of psoriasis on health care costs and patient work loss
Source:
Elsevier BV
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
Source:
Springer Science and Business Media LLC
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Source:
Massachusetts Medical Society
Pathogenesis and therapy of psoriasis
Source:
Springer Science and Business Media LLC
Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan.
Source:
Informa UK Limited
Impact of disease severity on work productivity and activity impairment in Japanese patients with psoriasis.
Source:
Elsevier BV
Etanercept and efalizumab for the treatment of psoriasis: a systematic review
Source:
National Institute for Health Research
A Meta-analysis
Source:
AMER MEDICAL ASSOC
An Evaluation of Clinical Economics and Cases of Cost-effectiveness
Source:
Japanese Society of Internal Medicine
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.